If one or more of the PIs reach the stage of clinical trials, they have the potential to become a promising therapeutic strategy in the treatment of various pathologies characterised by dysregulated TGF‐β signalling, including fibrotic diseases, asthma, COPD and certain cancers, especially immune‐cold and immune‐excluded cancers. The gene discussed is TGFB1; the disease is asthma.